跳至主要内容
临床试验/CTRI/2021/07/034839
CTRI/2021/07/034839尚未招募3 期

Role of stepwise titrated paclitaxel infusion schedule in the reduction of acute hypersensitivity reaction: A randomized controlled trial

CI AIIMS0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Adults patients with age between 18 years to 70 years
  • Histopathological diagnosis of cancer
  • Willing to participate and to give written informed consent
  • Naïve to conventional paclitaxel chemotherapy and planned to receive conventional paclitaxel either as single agent or in combination
  • ECOG performance status 0-2
  • Stable baseline vital signs: Afebrile, radial artery blood pressure (90/60 â?? 130/90mm Hg), pulse rate 60 â?? 100 / minutes, respiratory rate 12-18/ minutes, 97.8 °F to 99.1 °F (36.5° C to 37.3° C);

排除标准

  • Past history of hypersensitivity reaction to paclitaxel or cremophor containing drugs (cyclosporine, propofol, diazepam, teniposide, etoposide, Vitamin K) or partner drug or pheniramine or ranitidine
  • On chronic systemic steroids or received any dose in the last week
  • No history of hypersensitivity to partner drug
  • Hb < 8gm/dl, ANC < 1000/m3, creatinine > 2mg/dl, Bilirubin > 5 X ULN, transaminases 10 times or more

研究者

发起方
CI AIIMS

相似试验